+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Imugene Ltd (IMU) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 44 Pages
  • November 2023
  • GlobalData
  • ID: 1292032
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Imugene Ltd (IMU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Imugene Ltd (Imugene) is a clinical-stage biopharmaceutical company that focuses on the development of vaccines in the area of oncology. The company develops immunotherapies that activate the immune system of cancer patients to identify and eradicate tumors. The company develops products for the treatment of various tumors including gastric, breast, lung cancers. Imugene’s lead product candidate, CF33 is a chimeric vaccinia poxvirus for the treatment of mixed advanced solid tumors (MAST) and metastatic triple-negative breast cancer. It develops vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes recognized by an antibody with antitumor activity. Imugene is headquartered in Sydney, New South Wales Australia.

Imugene Ltd Key Recent Developments

Aug 21,2023: Cell Therapy Specialist Dr Bradley Glover Appointed as COO
Jul 19,2023: Imugene Oncolytic Virotherapy CF33 Patent Allowed in the US
Jul 18,2023: Imugene appoints Dr Ron Weitzman as Interim Chief Medical Officer
Apr 26,2023: Imugene receives $12.6m R&D tax refund

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Imugene Ltd - Key Facts
  • Imugene Ltd - Key Employees
  • Imugene Ltd - Key Employee Biographies
  • Imugene Ltd - Major Products and Services
  • Imugene Ltd - History
  • Imugene Ltd - Company Statement
  • Imugene Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Imugene Ltd - Business Description
  • R&D Overview
  • Imugene Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Imugene Ltd - Strengths
  • Imugene Ltd - Weaknesses
  • Imugene Ltd - Opportunities
  • Imugene Ltd - Threats
  • Imugene Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Imugene Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 21, 2023: Cell Therapy Specialist Dr Bradley Glover Appointed as COO
  • Jul 19, 2023: Imugene Oncolytic Virotherapy CF33 Patent Allowed in the US
  • Jul 18, 2023: Imugene appoints Dr Ron Weitzman as Interim Chief Medical Officer
  • Apr 26, 2023: Imugene receives $12.6m R&D tax refund
  • Mar 02, 2023: Imugene appoints CFO Mike Tonroe as Company Secretary
  • Oct 04, 2022: Imugene appoints Dr Giovanni Selvaggi as CMO
  • Oct 04, 2022: Imugene appoints Paul Wright as vice president CMC
  • Sep 07, 2022: Imugene appoints industry and drug development expert Dr Jakob Dupont as NonExecutive Director
  • Jul 18, 2022: Imugene appoints experienced life sciences CFO Mike Tonroe
  • Jul 01, 2022: Accomplished scientist Dr Sharon Yavrom appointed Executive Director, Clinical Scientist
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact Us
  • Disclaimer
List of Tables
  • Imugene Ltd, Key Facts
  • Imugene Ltd, Key Employees
  • Imugene Ltd, Key Employee Biographies
  • Imugene Ltd, Major Products and Services
  • Imugene Ltd, History
  • Imugene Ltd, Subsidiaries
  • Imugene Ltd, Key Competitors
  • Imugene Ltd, Ratios based on current share price
  • Imugene Ltd, Annual Ratios
  • Imugene Ltd, Annual Ratios (Cont...1)
  • Imugene Ltd, Interim Ratios
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Imugene Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Imugene Ltd, Ratio Charts
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Alterity Therapeutics Ltd
  • The Sustainable Nutrition Group Ltd
  • Rhinomed Ltd
  • Prescient Therapeutics Ltd
  • Kazia Therapeutics Ltd
  • Antisense Therapeutics Ltd